The 2003 WTO waiver decision was implemented in European Community law under regulation 816/2006 on the compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems, adopted in May 2006.
WTO vabastamisotsus rakendati Euroopa Ühenduse õiguses 2006. aasta mais vastu võetud määrusega 816/2006, milles käsitletakse tervishoiuprobleemidega riikidesse eksportimiseks toodetavate farmaatsiatoodete patentide sundlitsentsimist.